The safety and efficacy trial of nab-paclitaxel and trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer

Trial Profile

The safety and efficacy trial of nab-paclitaxel and trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2017 Status changed from recruiting to discontinued.
    • 19 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top